Out of these cases (15 tumors groups), BRAF fusions are most identified in glioma (29.5%), melanoma (23%), lung carcinoma (11.5%) and colorectal carcinoma (6.6%) (Supplementary Fig. S1)4,26,27. This evidence concerns the gene BRAF and glioma.